Page last updated: 2024-12-11

triacsin c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9576787
CHEMBL ID1952387
CHEBI ID144441
MeSH IDM0106599

Synonyms (33)

Synonym
triacsin c
fr-911190
ws-1228a
triacsin c from streptomyces sp.
ws 1228a
1-hydroxy-3-(2',4',7'-undecatrienylidine)triazene
2,4,7-undecatrienal, nitrosohydrazone, (?,e,e,e)-
2,4,7-undecatrienal, nitrosohydrazone, (e,e,e)-
76896-80-5
NCGC00189325-01
n-(undeca-2,4,7-trienylideneamino)nitrous amide
(2e,4e,7e)-2,4,7-undecatrienal nitrosohydrazone
fr 900190
2,4,7-undecatrienal nitrosohydrazone
CHEBI:144441
nitrosohydrazone-2e,4e,7e-undecatrienal
n-[(1e,2e,4e,7e)-undeca-2,4,7-trien-1-ylidene]nitrous hydrazide
(2e,4e,7e)-undecatrienal nitrosohydrazone
6m6d4602i5 ,
unii-6m6d4602i5
CHEMBL1952387
2,4,7-undecatrienal, nitrosohydrazone, (2e,4e,7e)-
fr-900190
NKTGCVUIESDXPU-YLEPRARLSA-N
AKOS024457120
DTXSID70894877
ws 1228a;fr 900190
CS-0028927
HY-N6707
2,4,7-undecatrienal nitrosohydrazone;ws1228a
triacsin c solution in dmso
triacsin c, lyophilized
AKOS040740448

Research Excerpts

Actions

Triacsin C alone did not increase PAF content. It did not modulate enzymatic activities of acytransferase, cholinephosphotransferase, acetylhydrolase or phospholipase A2.

ExcerptReferenceRelevance
"Triacsin C alone did not increase PAF content and did not modulate enzymatic activities of acytransferase, cholinephosphotransferase, acetylhydrolase, acetyltransferase or phospholipase A2."( Enhanced production of platelet-activating factor in stimulated rat leukocytes pretreated with triacsin C, A novel acyl-coA synthetase inhibitor.
Hayashi, M; Imai, Y; Naraba, H; Oh-ishi, S; Omura, S; Tomoda, H, 1992
)
1.22
"Triacsin C was found to inhibit the action of arachidonoyl-CoA synthetase and the nonspecific enzyme in sonicates of HSDM1C1 mouse fibrosarcoma cells."( Triacsin C: a differential inhibitor of arachidonoyl-CoA synthetase and nonspecific long chain acyl-CoA synthetase.
Hartman, EJ; Laposata, M; Omura, S, 1989
)
2.44

Treatment

Triacsin C treatment had no effect on basal or vasopressin-, angiotensin-II-, bradykinin- or ionomycin-induced release of radioactivity, but significantly reduced release in response to isoproterenol or phenylephrine. Pretreatment with triacsinC or merthiolate also enhanced the lyso-PAF content in the stimulated PMNs.

ExcerptReferenceRelevance
"Triacsin C treatment had no effect on basal or vasopressin-, angiotensin-II-, bradykinin- or ionomycin-induced release of radioactivity, but significantly reduced release in response to isoproterenol or phenylephrine."( Inhibiting long-chain fatty acyl CoA synthetase does not increase agonist-induced release of arachidonate metabolites from human endothelial cells.
Brady, M; Crumley, J; Moore, M; Stallone, JN; Weis, MT,
)
0.85
"Pretreatment with triacsin C or merthiolate also enhanced the lyso-PAF content in the stimulated PMNs."( Enhanced production of platelet-activating factor in stimulated rat leukocytes caused by the blockade of lysophospholipid acylation.
Hayashi, M; Imai, Y; Naraba, H; Oh-ishi, S, 1993
)
0.61
"Pretreatment with triacsin C (500 nM) for 1h enhanced production of platelet-activating factor in rat neutrophils, followed by stimulation with A23187 or fMLP."( Enhanced production of platelet-activating factor in stimulated rat leukocytes pretreated with triacsin C, A novel acyl-coA synthetase inhibitor.
Hayashi, M; Imai, Y; Naraba, H; Oh-ishi, S; Omura, S; Tomoda, H, 1992
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitorAn EC 6.2.1.* (acid-thiol ligase) inhibitor that interferes with the action of a long-chain-fatty-acid--CoA ligase (EC 6.2.1.3).
vasodilator agentA drug used to cause dilation of the blood vessels.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of retinoid isomerohydrolase (EC 3.1.1.64).
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
nitroso compoundCompounds having the nitroso group, -NO, attached to carbon, or to another element, most commonly nitrogen or oxygen.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
hydrazoneCompounds having the structure R2C=NNR2, formally derived from aldehydes or ketones by replacing =O by =NNH2 (or substituted analogues).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1066861Effect on mean extractable lipid mass in mouse bEND.3 cells at 1.5 uM relative to control2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1066856Inhibition of ACSL in mouse solubilized bEND.3 cells using [14C]-palmitic acid as substrate assessed as effect on total recovery of radioactive substrate at 1.5 uM after 2 hrs by liquid scintillation spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID1066858Inhibition of ACSL in mouse solubilized bEND.3 cells using [14C]-palmitic acid as substrate assessed as decrease in radioactivity in aqueous layer at 1.5 uM after 2 hrs by liquid scintillation spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID1066857Inhibition of ACSL in mouse solubilized bEND.3 cells using [14C]-palmitic acid as substrate assessed as increase in unincorporated radioactivity in media at 1.5 uM after 2 hrs by liquid scintillation spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID645244Virucidal activity against Rotavirus SA11 in MA104 cells assessed as reduction in viral titer at 100 uM pretreated for 2 hrs prior infection measured after 12 hrs postinfection by Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID645242Therapeutic index, ratio of TD50 for monkey MA104 cells to ED50 for Rotavirus SA112012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1066859Inhibition of ACSL in mouse solubilized bEND.3 cells assessed as inhibition of [14C]-palmitate incorporation into extractable lipids at 1.5 uM after 2 hrs by liquid scintillation spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID1066863Inhibition of Sprague-Dawley rat leukocytes recruitment assessed as inhibition of cell extravasation in unbranched post-capillary venules of mesentery at 5 uM measured at 120 mins2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID645243Virucidal activity against Rotavirus SA11 in MA104 cells assessed as reduction in viral titer at 100 uM pretreated for 2 hrs prior infection measured after 12 hrs postinfection by immunofluorescent assay2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1066872Inhibition of ACSL in mouse solubilized bEND.3 cells using [14C]-palmitic acid as substrate after 2 mins by liquid scintillation spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID645246Inhibition of lipogenesis in human HuH7 cells assessed as inhibition of increase in lipid droplets at 1 uM after 72 hrs by NBD-cholesterol based fluorescence analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1066867Inhibition of Sprague-Dawley rat leukocytes recruitment assessed as inhibition of cell rolling in unbranched post-capillary venules of mesentery at 5 uM measured at 120 mins2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID1066865Inhibition of Sprague-Dawley rat leukocytes recruitment assessed as inhibition of cell adhesion in unbranched post-capillary venules of mesentery at 5 uM measured at 120 mins2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury.
AID645245Inhibition of lipogenesis in monkey MA104 cells infected with Rotavirus SA11 assessed as inhibition of increase in lipid droplets at 1 uM after 10 hrs by NBD-cholesterol based fluorescence analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (3.36)18.7374
1990's29 (24.37)18.2507
2000's53 (44.54)29.6817
2010's27 (22.69)24.3611
2020's6 (5.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.04 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index53.51 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (39.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other117 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]